Evidence map›Paper›PMID 28100617›Full record

ArticleJournal of virology2017

Differences in Glycoprotein Complex Receptor Binding Site Accessibility Prompt Poor Cross-Reactivity of Neutralizing Antibodies between Closely Related Arenaviruses.

Rachel B Brouillette, Elisabeth K Phillips, Natarajan Ayithan, Wendy Maury

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Structure of the Lassa virus glycan shield provides a model for immunological resistance.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  13. Article
  14. Article
  15. Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rachel B BrouilletteDepartment of Microbiology, University of Iowa, Iowa City, Iowa, USA.
Elisabeth K PhillipsDepartment of Microbiology, University of Iowa, Iowa City, Iowa, USA.
Natarajan AyithanDepartment of Microbiology, University of Iowa, Iowa City, Iowa, USA.
Wendy MauryDepartment of Microbiology, University of Iowa, Iowa City, Iowa, USA wendy-maury@uiowa.edu.
University of Iowa · US

Funding

Training in Molecular Virology, Viral Pathogenesis and Viral VectorsT32AI007533 · NIAID · UNIVERSITY OF IOWA · PI Stanley Perlman · 1998 to 2026
$2.5M
Filoviral glycoprotein/cellular protein interactionsR01AI077519 · NIAID · UNIVERSITY OF IOWA · PI MAURY, WENDY JEAN · 2010 to 2014
$1.7M
NIAID NIH HHS R01 AI077519NIAID NIH HHS T32 AI007533
6 · The paper itself

Abstract

The glycoprotein complex (GPC) of arenaviruses, composed of stable signal peptide, GP1, and GP2, is the only antigen correlated with antibody-mediated neutralization. However, despite strong cross-reactivity of convalescent antisera between related arenavirus species, weak or no cross-neutralization occurs. Two closely related clade B viruses, Machupo virus (MACV) and Junín virus (JUNV), have nearly identical overall GPC architecture and share a host receptor, transferrin receptor 1 (TfR1). Given structural and functional similarities of the GP1 receptor binding site (RBS) of these viruses and the recent demonstration that the RBS is an important target for neutralizing antibodies, it is not clear how these viruses avoid cross-neutralization. To address this, MACV/JUNV chimeric GPCs were assessed for interaction with a group of α-JUNV GPC monoclonal antibodies (MAbs) and mouse antisera against JUNV or MACV GPC. All six MAbs targeted GP1, with those that neutralized JUNV GPC-pseudovirions competing with each other for RBS binding. However, these MAbs were unable to bind to a chimeric GPC composed of JUNV GP1 containing a small disulfide bonded loop (loop 10) unique to MACV GPC, suggesting that this loop may block MAbs interaction with the GP1 RBS. Consistent with this loop causing interference, mouse anti-JUNV GPC antisera that solely neutralized pseudovirions bearing autologous GP1 provided enhanced neutralization of MACV GPC when this loop was removed. Our studies provide evidence that loop 10, which is unique to MACV GP1, is an important impediment to binding of neutralizing antibodies and contributes to the poor cross-neutralization of α-JUNV antisera against MACV.

Indexed as

Amino Acid SequenceAnimalsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralBinding SitesChlorocebus aethiopsCross ReactionsHEK293 CellsHumansJunin virusMiceProtein BindingSpecies SpecificityVero CellsViral Fusion ProteinsAntibodies, NeutralizingAntibodies, ViralAntigens, ViralViral Fusion Proteinsarenavirusclade B virusesglycoproteinGPCJunín virusMachupo virusneutralizing antibodiesNew World arenavirus

Identifiers

PMID28100617
PMCPMC5355595
OpenAlexW2576851328

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.